Results 61 to 70 of about 53,390 (257)

Potential neuroprotective and therapeutic agents and their mechanisms for irradiation‐induced brain injury

Ibrain, EarlyView.
In this review, agents such baicalein, troxerutin, epigallocatechin gallate, quercetin, melatonin, valproic acid, lithium, neurosteroid progesterone, as well as minocycline have been implicated as neuroprotective agents for irradiation‐induced neurological deficits. Also, agents such as glucocorticoids, methylphenidate, vitamin E, bisdemethoxycurcumin,
Seidu A. Richard, Vivian Kapio Abem, Sagor Kumar Roy   +2 more
wiley   +1 more source

A comprehensive longitudinal analysis of changes during Attention Deficit Hyperactive Disorder pharmacological treatments: Relationships between clinical measures, QbCheck and Conners CPT‐II

JCPP Advances, EarlyView.
Abstract Background This study aims to evaluate the clinical value of using QbCheck in routine Attention Deficit Hyperactive Disorder (ADHD) clinics by investigating longitudinal inter‐domain relationships between objective neurocognitive outcomes of QbCheck and subjective clinical outcomes: ADHD core symptoms, impairment and quality of life (QoL ...
Seungjae Lee, Renee Testa, Beth Johnson, David Coghill   +3 more
wiley   +1 more source

Systematic review: Safety and efficacy of atomoxetine in children and adolescents with autism spectrum disorder

JCPP Advances, EarlyView.
This systematic review aimed to assess the current evidence on the efficacy and safety of Atomoxetine in common clinical symptoms of autism spectrum disorder (ASD) for children and adolescents. With limited studies available, there is a need for more high‐power studies for the use of Atomoxetine in children and adolescents with autism spectrum disorder.
Nihit Gupta, Daniel Boyes, Hunter Hanlon‐Taylor, Mayank Gupta   +3 more
wiley   +1 more source

Methylphenidate-induced Psychotic Symptoms in 65-Year-Old Female with ADHD

Iranian Journal of Psychiatry, 2018
Methylphenidate, a stimulant, is prescribed commonly in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. Methylphenidate is generally considered a safe medication, however, some rare adverse effects, such as ...
Elliyeh Ghadrdan, Maryam Mousavi, Padideh Ghaeli   +2 more
doaj  

A randomised controlled trial of combined EEG feedback and methylphenidate therapy for the treatment of ADHD

Swiss Medical Weekly, 2013
PURPOSE: To evaluate the efficacy of combined methylphenidate and EEG feedback treatment for children with ADHD. METHODS: Forty patients with ADHD were randomly assigned to the combination group (methylphenidate therapy and EEG feedback ...
Li Li, Li Yang, Chuan-jun Zhuo, Yufeng Wang   +3 more
doaj   +1 more source

Methylphenidate-Induced Oculogyric Crisis in a Patient with Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder: A Case Report

Psychiatry and Clinical Psychopharmacology, 2021
Methylphenidate is one of the agents used in the treatment of attention deficit hyperactivity disorder. In the literature, the following side effects were reported from the use of methylphenidate: sleep and appetite problems, blood pressure and heart ...
Nilfer Sahin, Damla Balkan, Azat Duman
doaj   +1 more source

Differences in patterns of attention deficit/hyperactivity disorder medication use in US children

JCPP Advances, EarlyView.
Abstract Background Understanding attention deficit/hyperactivity disorder (ADHD) medication patterns is crucial for optimizing treatment outcomes. There are limited data on racial, ethnic, gender and socioeconomic treatment differences across longitudinal national samples.
Jennie E. Ryan, Alexander Weigard, Sean Esteban McCabe, Timothy E. Wilens, Philip T. Veliz   +4 more
wiley   +1 more source

Effects of Extended-Release Methylphenidate on Dopamine and Norepinephrine Transporters in Adults With Attention-Deficit/Hyperactivity Disorder: A Longitudinal Dual-Tracer PET Study. [PDF]

Psychiatry Clin Neurosci
Aim Attention‐deficit/hyperactivity disorder (ADHD) is associated with dysregulation of dopamine and norepinephrine neurotransmission. Extended‐release methylphenidate (MPH), a first‐line treatment for ADHD, modulates these systems. However, its specific effects on the dopamine transporter (DAT) and norepinephrine transporter (NET) are inadequately ...
Oya M, Matsuoka K, Kubota M, Kitamura S, Kataoka Y, Kokubo N, Takahata K, Seki C, Endo H, Tagai K, Takado Y, Hirata K, Ichihashi M, Kurose S, Kato N, Sugihara G, Shimizu M, Takagi S, Ito W, Nakamura M, Higuchi M, Takahashi H.   +21 more
europepmc   +2 more sources

Attention‐deficit hyperactivity disorder in children and young persons during the COVID‐19 pandemic. A temporal trends analysis of electronic heath records in Greater Manchester, England

JCPP Advances, EarlyView.
Abstract Background The incidence of attention‐deficit hyperactivity disorder (ADHD) in children and young people has increased in recent years. Disease frequency varies according to sociodemographic characteristics. There are seasonal patterns in ADHD diagnosis and prescribing with rates falling during school holidays.
Louise Hussey, Evangelos Kontopantelis, Pearl L. H. Mok, Darren M. Ashcroft, Shruti Garg, Carolyn A. Chew‐Graham, Karina Lovell, Roger T. Webb   +7 more
wiley   +1 more source

Reporting a Case of Injecting Methylphenidate (Ritalin) Tablets, Intensified Symptoms of Schizoph-renia or Induce Separate Mental Disorder [PDF]

Addiction and Health, 2010
Background: Methylphenidate is one of the classic amphetamines which can cause or exacerbate psychotic symptoms in schizophrenia patients. Methods: In this paper, a young man is presented with injection of methylphenidate tablets with acute ...
Alireza Ghaffarinejad, Ali Kheradmand
doaj